Prospective cohort study evaluating risk factors for the development of pasture-associated laminitis in the United Kingdom by Menzies-Gow, N J et al.
  
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is the peer reviewed version of the following article: 
Menzies-Gow, N. J., Harris, P. A. and Elliott, J. (2016), Prospective cohort study evaluating 
risk factors for the development of pasture-associated laminitis in the United Kingdom. 
Equine Vet J. doi:10.1111/evj.12606 
This article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Self-Archiving. 
The full details of the published version of the article are as follows: 
 
TITLE: Prospective cohort study evaluating risk factors for the development of pasture-
associated laminitis in the United Kingdom 
AUTHORS: Menzies-Gow, N. J., Harris, P. A. and Elliott, J.  
JOURNAL TITLE: EQUINE VETERINARY JOURNAL 
PUBLISHER: Wiley 
PUBLICATION DATE: 25 August 2016 (online) 
DOI: 10.1111/evj.12606 
1 
 
Prospective cohort study evaluating risk factors for the development of pasture-associated laminitis 1 
in the UK 2 
N.J Menzies-Gow, P.A. Harris* and J. Elliott 
Royal Veterinary College, London UK.   
*Equine Studies Group, WALTHAM Centre for Pet Nutrition, UK. 
 
Corresponding Author: nmenziesgow@rvc.ac.uk 
 
Keywords (6): horse, laminitis, insulin, adiponectin, IGF-1, dexamethasone 
 
Word Count: 3861 
 
Ethical considerations: This study follows international, national, and/or institutional guidelines for 
humane animal treatment and complies with relevant legislation in the country in which the study 
was conducted. It was approved by the ethics review committee at the institution at which the studies 
were conducted and was performed under the UK Veterinary Surgeons Act.  Informed owner consent 
was obtained for all animals included in the study. 
 
Competing Interests: Professor Harris is employed by one of the study funders. 
 
Source of Funding: PetPlan Charitable Trust, British Veterinary Association Animal Welfare Foundation 
Norman Hayward Fund, Laminitis Trust and WALTHAM Centre for Pet Nutrition 
 
2 
 
Acknowledgements: Some of this data was presented at the European College of Equine Internal 
Medicine Annual Congress 2015. The authors would like to thank Miss Katya Potter for her help in 
collecting data. 
 
Authorship: The study was designed by Dr Menzies-Gow and Professors Elliott and Harris. Dr Menzies-
Gow executed the study. Data analysis and interpretation, and preparation of the manuscript were 
undertaken by Dr Menzies-Gow and Professors Elliott and Harris. 
3 
3 
 
Summary  4 
Background: Certain individuals appear predisposed to recurrent pasture-associated laminitis. 5 
Reasons for performing the study: Previous studies have predominantly investigated risk factors only 6 
after disease occurrence. 7 
Objectives: To investigate pasture-associated laminitis risk factors prior to disease occurrence. 8 
Study design: Prospective cohort study. 9 
Methods: Non-laminitic ponies >7 years old were recruited. Body condition score (BCS), height, 10 
weight, crest height and thickness were measured and an overnight dexamethasone suppression test 11 
performed. Plasma/serum adiponectin, leptin, triglyceride, basal insulin, insulin post dexamethasone, 12 
insulin-like growth factor (IGF)-1, IGF binding protein (IGFBP)-1, IGFBP-3, C-reactive protein, von 13 
Willebrand’s factor (vWF), soluble (s) E-selectin and p-selectin concentrations were assayed. Follow-14 
up was obtained from owners annually for 3 years to ascertain occurrence of veterinary-diagnosed 15 
pasture-associated laminitis. Data were analysed by multivariate logistic regression. ROC curves 16 
analysis was performed for significant risk factors and cut off values determined.  17 
Results: 446 animals were recruited; the median (interquartile range) age was 15 (10, 20) years; 50.4% 18 
were mares and 49.6% geldings; the most common breeds were Welsh (36%), Shetland (17%) and cob 19 
(9%); 72.2% were overweight/obese (BCS 7-9/9), 27.3% ideal weight (BCS 4-6/9) and 0.5% 20 
underweight (BCS 1-3/9). After 1, 2 and 3 years, 18 (4%), 30 (7%) and 44/446 (10%) animals had had 21 
laminitis. Plasma/serum [adiponectin],basal [insulin] and [insulin] post dexamethasone were 22 
significantly (p<0.05) associated with laminitis occurrence cumulatively after 1, 2 and 3 years. The 23 
accuracy to separate animals who did or did not develop laminitis determined using the area under 24 
the ROC curves was good (basal [insulin] after 1 year), fair (all others) or poor ([insulin] post 25 
dexamethasone).  26 
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Main limitations: Animals were evaluated at a single time point and biomarkers were assayed using 27 
single assays. 28 
Conclusions: Risk factors for future laminitis prior to disease occurrence include low plasma 29 
adiponectin and high serum basal insulin or insulin post dexamethasone concentrations.  30 
 31 
Introduction  32 
A metabolic phenotype with similarities to human metabolic syndrome (HMS), including insulin 33 
dysregulation (ID) [1], dyslipidaemia [2-4] and altered circulating adipokine concentrations [5-7] with 34 
or without obesity appears to be associated with an increased risk of laminitis [8; 9]. Thus the same 35 
pathologic mechanisms that underlie the cardiovascular diseases associated with HMS, including 36 
changes in insulin signalling, inflammatory cytokines and endothelial dysfunction, could contribute to 37 
laminitis risk. Multiple variables have been evaluated previously as laminitis risk factors [2-4]; [10], but 38 
these studies have evaluated animals after disease occurrence and differences detected could reflect 39 
the disease rather than a predisposition. Identifying risk factors prior to disease occurrence would 40 
allow targeting of preventive management strategies. Potential risk factors requiring investigation 41 
include obesity, ID, inflammatory cytokines and markers of endothelial dysfunction. 42 
Intravenous infusion methods for ID identification are not practical in the field [11]. The 43 
dexamethasone suppression test is a potential dynamic test for ID as exogenous cortisol analogues 44 
antagonise insulin’s actions resulting in increased endogenous insulin secretion. Previously laminitic 45 
ponies (PLP) had a greater increase in insulin concentration post dexamethasone compared to 46 
controls [12] in spring and summer [13]. Concentrations of the anti-inflammatory marker adiponectin 47 
were significantly lower and plasma triglyceride concentrations were significantly higher in PLP in late 48 
spring and winter [4].  49 
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Leptin is an adipose-derived hormone [14]; hyperleptinaemia in humans is associated with HMS, ID, 50 
vascular inflammation [15] and endothelial dysfunction [16]. Insulin-like growth factor (IGF)-1 has 51 
insulin-like metabolic actions and lower IGF-1 concentrations are associated with human obesity, ID 52 
and HMS [17]. IGF binding proteins (IGFBPs) represent an important link between the insulin and IGF 53 
systems and play important roles in human obesity and HMS [18]. Abnormal IGFBP expression is a 54 
sensitive marker of ID, used to identify individual humans with ID at high cardiovascular risk and as an 55 
early marker of HMS [18]. None of these factors/parameters has been assessed as predictors of 56 
laminitis development prospectively. 57 
The current gold standard non-invasive test of assessing endothelial function using endothelial-58 
dependent vasomotion in humans is flow mediated dilatation, however  it is not suitable for equine 59 
use due to a lack of accuracy or precision [19]. Additionally, various circulating molecules are used as 60 
biomarkers of endothelial dysfunction including von Willebrand’s factor (vWF) [20], soluble (s)E-61 
selectin [21] and P-selectin [22]. Thus it would be logical to evaluate these in animals prior to laminitis 62 
occurrence. 63 
The study aim was to investigate prospectively certain risk factors for the development of pasture-64 
associated laminitis in a cohort of animals with no known history of laminitis, including morphometric 65 
measures of obesity and circulating concentrations of biomarkers of insulin dysregulation, adipokines 66 
and endothelial dysfunction. 67 
 68 
Materials and Methods 69 
The study was approved by Royal Veterinary College Ethics and Welfare Committee and was 70 
performed under the UK Veterinary Surgeons Act 1966. So that the dexamethasone suppression test 71 
was performed for the benefit of the individual animal as a test for pituitary pars intermedia 72 
6 
 
dysfunction (PPID) and due to the fact that the youngest age of a case of PPID in the scientific literature 73 
is 7 years [23; 24], only animals >7 years old could be included in the study. 74 
 75 
Animals 76 
Sample size calculations assuming 80% power and 95% confidence indicated that 200-700 animals 77 
were required to detect a 5- to 10-fold increase in laminitis risk in ID compared to non-ID animals 78 
(assuming 2% laminitis risk over 2 years in non-ID animals and exposed:unexposed ratio of 1:10). Thus 79 
the prospective cohort study aimed to recruit approximately 400 client-owned ponies >7 years old 80 
with no previous known history of laminitis to the study. Animals were not cases nor were they 81 
recruited via veterinary practices or referral hospitals. Instead they were healthy animals recruited to 82 
the study directly from owners in response to posts on social media sites, requests placed in equine 83 
lay magazines and letters sent to all equine charities and riding/livery establishments within a 50 mile 84 
radius of the Royal Veterinary College by the study organiser. All suitable animals were included in the 85 
study and there was no randomisation. A standard clinical examination of each animal was performed 86 
by a single experience equine veterinarian and ponies were excluded if they displayed clinical signs of 87 
acute, chronic or previous laminitis (including lameness affecting 2 or more feet, increased digital 88 
pulses, characteristic stance of leaning back on the heels, divergent hoof growth rings) or pituitary 89 
pars intermedia (PPID; including hypertrichosis) at the time of recruitment to the study. In addition, 90 
ponies were excluded from the study if they were subsequently identified as having an abnormal 91 
cortisol response to the dexamethasone suggestive of PPID. The study was fully explained to the 92 
owners, a factsheet provided and informed consent obtained. Historical information was obtained by 93 
direct questioning of the owner. All animals were evaluated and samples collected in summer 94 
(August). 95 
 96 
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Weight, condition score and crest measurements 97 
A measuring stick was used to measure the height of the ponies at the withers and the weight of the 98 
ponies was estimated using a weigh tapea around the girth. Body condition score (BCS) was assessed 99 
by a single experienced equine veterinarian giving a grade on a scale of 1 to 9 [25] over 6 areas of the 100 
body and then calculating the mean. Callipers were used to measure the height and thickness of the 101 
crest of the neck above the nuchal ligament at the point half way between the poll and the withers.  102 
 103 
Overnight dexamethasone suppression test 104 
Blood samples were collected by jugular venepuncture before and 19 hours after the intramuscular 105 
administration of dexamethasoneb (44 g/kg). 106 
 107 
Blood sample collection 108 
Jugular venous blood samples were collected into EDTA and heparinised vacutainer tubesc for plasma 109 
separation and into plain vacutainer tubes for serum preparation. Plasma tubes were kept in ice until 110 
centrifugation at 3,000 x g for 10 minutes. Plasma was harvested, aliquoted and frozen at -80°C until 111 
analysed. Serum tubes were incubated in a 37°C water bath for 30 minutes, centrifuged, aliquoted 112 
and frozen at -80°C.   113 
 114 
Mediator Analysis 115 
Plasma adiponectind [26] and leptine [26] and serum insulinf [27] concentrations were measured using 116 
radioimmunoassays. Plasma total IGF-1,g IGFBP-1,h IGFBP-3,i C-reactive proteinj [28], P-selectink and  117 
sE-selectinl concentrations were measured using ELISAs. Plasma triglyceride concentrations were 118 
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measured by the pathology laboratory at Bell Equine Veterinary Clinic, Kent, UK and plasma vWF 119 
antigen concentrations were measured by a commercial laboratorym. All of these methods have been 120 
previously validated for use in the horse apart from IGF-1, IGFBP-1, IGFBP-3, sE-selectin and P-selectin. 121 
Thus these assays were validated by determining intra- and inter-assay variability (to assess precision 122 
and repeatability; using pooled samples from 5 animals measured three times), dilutional parallelism 123 
(using samples from 5 animals diluted 1 in 2, 1 in 4 and 1 in 8 within the working range of the assay) 124 
and spiked recovery (to assess specificity; using the assay standard diluted in equine plasma).  125 
 126 
Follow up 127 
Owners of animals recruited to the study were contacted after 12, 24 and 36 months in order to 128 
ascertain whether individual animals had suffered from pasture-associated laminitis diagnosed by a 129 
veterinarian in the preceding 12 months.  130 
 131 
Data Analysis 132 
Data were analysed using the SPSS software programn.  Univariable logistic regression was first used 133 
to assess risk factors including morphometric data and blood analytes associated with the outcome 134 
(namely laminitic after 1 year or not; laminitic after 2 years or not; laminitic after 3 years or not) 135 
individually. Correlations between those risk factors with p<0.1 were tested by calculating Pearson’s 136 
correlation coefficient. Interactions between risk factors were tested by calculating A*B for significant 137 
risk factors and entering risk factors A and B and A*B into a multivariable logistic regression model. If 138 
the p value for the interaction term A*B was >0.05, there was not significant interaction between risk 139 
factors A and B. Risk factors with p<0.1 were then entered into a multivariable logistic regression and 140 
any risk factors with p>0.05 sequentially removed until all the risk factors had p<0.05 in the final 141 
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model. ROC curves were constructed for those risk factors remaining in the final model. The accuracy 142 
of the test to separate animals into those which did or did not subsequently develop laminitis was 143 
determined by calculating the area under the curve (AUC) whereby an area of 0.90-1 is excellent, 0.80-144 
0.90 good, 0.70-0.80 fair, 0.60-0.70 poor and 0.50-.60 fail [29]. In addition, the co-ordinates of the 145 
ROC curve were then used to determine the cut off value which maximised specificity and sensitivity 146 
and the corresponding positive (PPV) and negative predictive values (NPV) using these cut-off values 147 
were calculated. 148 
 149 
Results 150 
Four hundred and forty six ponies aged (median [interquartile range]) 15 (10, 20) years were recruited 151 
to the study. Of these 50.4% were mares and 49.6% were geldings. A range of pony breeds were 152 
represented including Welsh (36.4%), Shetland (17%), cob (9.4%), New Forest (9%), crossbreed (7.6%) 153 
and other (20.6%). The majority (72.2%) of animals were overweight or obese (BCS 7-9), with 27.3% 154 
being ideal weight (BCS 4-6) and 0.5% being underweight (BCS 1-3). 155 
 156 
After 1, 2 and 3 years cumulatively 18 (4%), 30 (7%) and 44 (10%) had developed pasture-associated 157 
laminitis, 416 (93%), 374 (84%) and 348 (78%) remained non laminitic, and 12 (3%), 42 (9%) and 54 158 
(12%) had been euthanased for reasons other than laminitis, respectively. 159 
 160 
Values for crest height, crest thickness, body condition score, plasma/serum concentrations of 161 
biomarkers and serum insulin response to an overnight dexamethasone suppression test in all animals 162 
and those that subsequently developed laminitis and those that remained non laminitic after 1, 2 and 163 
3 years are shown in Table 1.   164 
10 
 
 165 
The validation of the ELISAs used to measured plasma IGF-1, IGFBP-1, IGFBP-3, sE-selectin and P-166 
selectin concentrations revealed that they performed satisfactorily (Online supplementary 167 
information, table 1). 168 
 169 
Most of the pairwise correlations were weak (Pearson’s correlation coefficient <0.2) apart from basal 170 
insulin and insulin post dexamethasone (Pearson’s correlation coefficient 0.68). The only significant 171 
interaction between risk factors was between basal insulin and post dexamethasone insulin 172 
concentration after 2 (p=0.03) and 3 years (p=0.02). 173 
 174 
For the data obtained after 1 year, the risk factors taken into the multivariate regression analysis 175 
included plasma/serum adiponectin, basal insulin, insulin post dexamethasone and p-selectin 176 
concentrations. Apart from p-selectin, these all proved to be significant risk factors for the 177 
development of laminitis and so remained in the multivariate analysis (Table 2). 178 
 179 
For the data obtained after 2 years, the risk factors taken into the multivariate regression analysis 180 
included plasma/serum CRP, adiponectin, IGF-1, basal insulin and insulin post dexamethasone 181 
concentrations. Those that proved to be significant risk factors for the development of laminitis and 182 
so remained in the multivariate analysis were plasma adiponectin, plasma IGF-1, serum basal insulin 183 
and serum insulin post dexamethasone concentrations (table 2).   184 
 185 
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For the data obtained after 3 years, the risk factors taken into the multivariate regression analysis 186 
included plasma/serum adiponectin, basal insulin, insulin post dexamethasone and IGFBP-3 187 
concentrations. Apart from IGFBP-3, these all proved to be significant risk factors for the development 188 
of laminitis and so remained in the multivariate analysis (Table 2)  189 
 190 
None of the morphometric data proved to be significant risk factors for the development of laminitis 191 
in 1, 2 or 3 years. 192 
 193 
The ROC AUC and the cut off values which maximised the specificity and the sensitivity, as well as the 194 
corresponding PPV and NPV are shown in Table 3. There was no improvement in these values when 195 
variables were combined. 196 
 197 
Discussion 198 
Consistent risk factors for the future development of laminitis in animals prior to disease occurrence 199 
in the present study included low plasma adiponectin and high basal and post dexamethasone serum 200 
insulin concentrations.  201 
 202 
The hormone adiponectin has anti-diabetic, anti-atherogenic and anti-inflammatory properties in 203 
humans and rodents [30; 31] and circulating concentrations are decreased in obese individuals and in 204 
patients with HMS [32], type 2 diabetes [30] and cardiovascular disease [33]. Despite being specifically 205 
secreted by adipocytes, a strong negative correlation exists between adiponectin concentrations and 206 
the BMI of human patients [34; 35] with a similar observation made in horses [26]. Previously laminitic 207 
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ponies have been shown to have significantly lower plasma adiponectin concentrations compared to 208 
non-laminitic ponies irrespective of season [4]. Lower plasma adiponectin concentrations may 209 
promote a decreased anti-inflammatory capacity in previously affected horses. We report for the first 210 
time that lower adiponectin concentrations occur in animals prior to clinical signs of laminitis 211 
indicating that hypoadiponectinaemia may be a risk factor for laminitis rather than solely a 212 
consequence of the disease. ROC curve analysis revealed that the accuracy of adiponectin 213 
concentrations to separate animals into those which do or do not go on to develop laminitis in 1, 2 or 214 
3 years was fair and a cut of value of 2.50g/ml gave acceptable sensitivity (78%) and specificity (79%) 215 
values. 216 
 217 
The link between hypoadiponectinaemia and laminitis risk in the present study was not due to obesity 218 
as obesity was not a risk factor of laminitis and there was no correlation between plasma adiponectin 219 
concentrations and morphometric measures of obesity. In other species, adiponectin promotes 220 
vasorelaxation through increased vascular expression of endothelial nitric oxide (NO) synthase and 221 
prostacylin (PGI2) synthase [36] and via opening of smooth muscle cell K+ channels [37]. Thus, low 222 
adiponectin concentrations may increase the risk of future laminitis through decreased vasorelaxation 223 
of the equine digital vasculature. Alternatively, there is evidence in humans that there is cross-talk 224 
between adiponectin and both the insulin (InsR) and IGF-1 (IGF-1R) receptors [38]. Adiponectin in 225 
association with insulin is able to induce activation of InsR and IGF-1R and activate the downstream 226 
intracellular signalling pathways [38]. Supraphysiologic hyperinsulinaemia causes laminitis in healthy 227 
equids [39]; at high concentrations insulin can bind to and activate InsR, IGF-1R and InsR/IGF-1R [40]; 228 
and IGF-1R and InsR have been detected in lamellar epithelial and endothelial cells respectively [41]. 229 
Thus, hypoadiponectinaemia and hyperinsulinaemia could potentially combine to alter lamellar 230 
epithelial and endothelial InsR and IGF-1R expression resulting in epithelial proliferation and 231 
endothelial dysfunction and consequent laminitis. These hypotheses require further investigation.  232 
13 
 
 233 
The link between laminitis and insulin dysfunction has been investigated and hyperinsulinaemia 234 
and/or insulin dysregulation has been reported in previously laminitic animals in a number of studies 235 
[2; 3; 42]. Hyperinsulinaemia and insulin dysregulation may predispose to laminitis by triggering 236 
disturbances in vascular function through downregulation of the phosphatidylinositol 3-kinase (PI-3K) 237 
pathway and hence reduction in production of the vasodilator nitric oxide (NO) in the face of 238 
continued vasoconstrictor production [43]. Alternatively, as previously discussed, insulin may be 239 
excessively stimulating lamellar IGF-1 receptors, leading to inappropriate epithelial cell proliferation 240 
with lamellar weakening and consequent laminitis [44]. Previously, serum basal insulin concentrations 241 
>32iu/ml had good sensitivity (100%) and specificity (80%) for predicting clinical laminitis in the 242 
following 3 months in previously laminitic animals [6]. Similarly, in the present study increased serum 243 
insulin concentrations in non-laminitic animals was significantly associated with the subsequent 244 
development of laminitis. ROC curve analysis revealed that the accuracy of serum basal insulin 245 
concentration to separate animals into those which do or do not go on to develop laminitis 246 
cumulatively in 1, 2 or 3 years was good (after 2 years) to fair (after 1 and 3 years) and a cut of value 247 
of 21.8iu/ml gave acceptable sensitivity (78%) and specificity (67%) values. This value is virtually 248 
identical to that proposed as a value above which is consistent with insulin dysregulation previously 249 
[9]. However it must be acknowledged that animals in the present study were not fasted prior to blood 250 
sampling. 251 
 252 
Single measurements of serum insulin concentration are affected by a number of factors including 253 
diet, exercise, stress and time of day [11; 45]. Thus dynamic tests of endocrine function are often 254 
advocated to detect ID. The dexamethasone suppression test (DST) is a potential dynamic test for ID 255 
as exogenous cortisol analogues antagonise insulin resulting in increased endogenous insulin 256 
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secretion. Previously laminitic ponies had a greater increase in serum insulin post dexamethasone 257 
compared to control ponies [12] which was seen only in spring and summer [13] and a cut off value of 258 
75iu/ml was suggested to distinguish groups of previously laminitic animals from controls. Similarly 259 
in the present study, an exaggerated insulin response to dexamethasone was associated with the 260 
subsequent development of laminitis in non laminitic ponies. ROC curve analysis revealed that the 261 
accuracy of serum insulin post dexamethasone to separate animals into those which do or do not go 262 
on to develop laminitis cumulatively in 1, 2 or 3 years was fair to poor and a cut of value of 105.6iu/ml 263 
gave fair sensitivity (69%) and specificity (68%) values for the development of laminitis in the next 12 264 
months. It should be acknowledged that the study was designed prior to the recent increase in 265 
popularity of oral sugar or glucose tests as a dynamic test of ID. To the authors’ knowledge the insulin 266 
response to dexamethasone has not been directly compared to the OGT or OST, thus it is not possible 267 
to extrapolate these results to those tests. 268 
 269 
Insulin-like growth factor (IGF)-1 is primarily produced in the liver from growth hormone metabolism 270 
prior to secretion into the circulation. It has short-term insulin-like metabolic actions and long-term 271 
growth factor-like effects on cell proliferation and differentiation. Lower IGF-1 concentrations are 272 
associated in other species with obesity, insulin resistance, HMS [17], type 2 diabetes [46] and 273 
increased risk of cardiovascular disease [47]; however the precise mechanism(s) behind these 274 
apparent inverse relationships remains elusive. The median plasma IGF-1 concentrations in those 275 
animals that remained non-laminitic in the present study were similar to those previously reported in 276 
adult horses [48; 49]; whilst the median plasma IGF-1 concentrations in those ponies that 277 
subsequently developed laminitis after 2 years was significantly lower. Plasma IGF-1 concentrations 278 
have not been measured in previously laminitic ponies; however season and body condition score 279 
have been shown to have an effect in other populations of horses [50; 51]. Plasma IGF-1 280 
concentrations were significantly higher in the summer compared to the winter [50] and in overweight 281 
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compared to underweight mares [51]. In the present study, samples were collected from all of the 282 
ponies at the same time of the year (August) and body condition score was not a risk factor for 283 
laminitis development. Whilst in people, IGF-1 concentrations have been reported to decrease with 284 
age [52], there is no evidence for aging being a factor in changes of IGF-1 in adult horses [48] or in the 285 
present study population. Thus it would appear that for unknown reasons low IGF-1 concentrations 286 
were only associated with an increased risk of developing laminitis after 2 years and not after 1 or 3 287 
years suggesting that IGF-1 concentration is not directly associated with an increased risk. 288 
 289 
There are six IGF binding proteins (IGFBPs) which link with IGF-1 and -2 and prevent them from being 290 
degraded; they also facilitate IGF transport through body compartments. The interaction between 291 
IGFs and their specific receptors is partly regulated by structural modifications inherent to the IGFBPs. 292 
Whilst IGFBP expression has been suggested to be useful as a sensitive marker of ID, to identify 293 
individuals with ID at high cardiovascular risk and as an early marker of HMS [18], concentrations of 294 
IGFBP-1 or IGFBP-3 were not useful in the detection of animals at increased risk of development of 295 
future laminitis. 296 
 297 
Leptin is an adipose tissue derived hormone [14] and hyperleptinaemia is associated with HMS, insulin 298 
resistance, vascular inflammation [15] and endothelial dysfunction [16]. In horses and ponies, 299 
hyperleptinaemia is associated with hyperinsulinaemia [53], obesity [54] and previous laminitis in 300 
some [6], but not all studies [7]. In addition, hyperleptinaemia could be used to predict clinical laminitis 301 
in the following 3 months in previously laminitic animals [6].  However, whilst there was a weak 302 
positive correlation between plasma leptin concentration and BCS (p=0.03, r=0.14), no such 303 
correlation with serum insulin concentration was found and there was no association between plasma 304 
leptin concentrations and subsequent development of laminitis was apparent in the present study.  305 
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 306 
Increased plasma triglyceride concentrations are associated with hyperinsulinaemia [53], obesity [54] 307 
and previous laminitis [2-4]. However in agreement with the present study, they were not beneficial 308 
in the prediction of clinical laminitis in the following 3 months in previously laminitic animals [6].   309 
 310 
C-reactive protein (CRP) is an acute-phase protein and increased concentrations are associated with 311 
insulin resistance [55], HMS [56; 57] and cardiovascular disease [58]. In horses, an increase in CRP 312 
concentration has been reported in induced inflammation and laminitis, pneumonia, enteritis, 313 
arthritis and after castration [59]. Other studies, however, reported that serum CRP concentration was 314 
not affected by inflammatory disease [60; 61]. CRP concentrations have not been evaluated in 315 
association with naturally occurring laminitis, but CRP concentrations were not significantly different 316 
between control animals and hyperinsulinaemic obese horses [62]. The concentrations found in the 317 
present study were similar to those reported in healthy horses in one study [28], but lower than those 318 
reported in another [62] and they were not found to be a significant risk factor for the subsequent 319 
development of laminitis. 320 
 321 
Equine plasma vWF antigen concentrations have only been previously measured in association with 322 
exercise [20] or as part of the investigation of clotting disorders [63; 64]. In humans, vWF 323 
concentrations are increased in obesity [65], HMS [66] and insulin resistant patients [67]. However 324 
plasma vWF antigen concentrations could not be used to predict the development of HMS in patients 325 
with hypertension [68]. P-selectin and sE-selectin are markers of endothelial dysfunction in other 326 
species [21; 22] and the role of endothelial dysfunction is important in HMS and ID and the 327 
development of associated cardiovascular  diseases [69]. Thus, it is logical to postulate that endothelial 328 
dysfunction may play a role in the pathogenesis of laminitis associated with ID. However, none of the 329 
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biomarkers of endothelial dysfunction measured were associated with the subsequent development 330 
of laminitis in the present study. 331 
 332 
Whilst an association between previous laminitis and generalised and/or regional adiposity has been 333 
reported [2; 6; 70] and generalised and/or regional adiposity could be used to predict clinical laminitis 334 
in the following 3 months in previously laminitic animals [6], surprisingly no such association with 335 
future laminitis was found in the present study. It should be acknowledged that the majority (72%) of 336 
ponies in the study were overweight or obese, which is similar to previously reported figures of obesity 337 
within the UK pony population in some studies [71], but much greater than those in other studies 338 
evaluating both horses and ponies (30-45%) [72-75]. This high prevalence of obesity may have resulted 339 
in it not being a discernible risk factor within the population studied; alternatively obesity alone may 340 
not a significant risk factor for the future development of laminitis. 341 
 342 
The main limitation of the present study was that animals were only examined at a single point in 343 
time. There is no current evidence for the longevity or stability of these biomarkers in horses and it is 344 
possible that both these and the morphometric data values changed considerably during the 3 years 345 
over which the animals were subsequently followed which could in turn have had a significant impact 346 
on the laminitis risk.  347 
 348 
In conclusion, risk factors for the development of laminitis in previously non-laminitic animals in the 349 
present study included low plasma adiponectin as well as high basal insulin and serum insulin post 350 
dexamethasone concentrations. The accuracy of these to separate animals who did or did not develop 351 
laminitis after 1, 2 or 3 years was good (serum basal [insulin] after 1 year), fair (all others) or poor 352 
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(serum [insulin] post dexamethasone) and cut off values with acceptable sensitivities and specificities 353 
were generated. Combinations of these biomarkers did not improve their predictive value. However 354 
it should be acknowledged that these cut-off values were generated using samples obtained at a single 355 
time of the year (summer) and measured using single assays (radioimmunoassay) and radiography 356 
was not performed so that it is possible that animals with pre-existing subclinical laminitis were 357 
included. Surprisingly, the development of laminitis was not associated with regional or generalised 358 
obesity, hyperleptinaemia or hypertriglyceridaemia. In addition there was no association with 359 
circulating CRP, IGF-1, IGFBP-1, IGFBP-3, sE-selectin, p-selectin or vWF antigen concentrations. Further 360 
prospective cohort studies that examine animals more frequently such that their morphometric and 361 
metabolic variables are determined within a shorter time frame in relation to the onset of laminitis or 362 
that include a much larger number of animals are warranted to assess these risk factors further. 363 
 364 
Manufacturers’ Details 365 
a Weigh tape, Equi Life Ltd, Mead House, Dauntsey, Chippenham, Wilts. UK 366 
b Colvasone, Norbrook Laboratories (GB) Ltd, Carlisle, UK 367 
c Vacutainer, Becton-Dickinson Ltd, Oxford, UK 368 
d Adiponectin RIA kit, Merck Millipore, Missouri 369 
e Multi-species leptin RIA kit, Merck Millipore, Missouri 370 
f Coat-a-count insulin assay, Diagnostic Products Corp, Los Angeles, California 371 
g Human IGF-1ELISA, Mediagnost, Reutlingen, Germany  372 
h Equine IGFBP-1 ELISA, BlueGene Biotech, Shanghai, China 373 
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Table 1 
Median (interquartile range) or mean + SD values for morphometric and metabolic variables measured in 446 non-laminitic ponies that either remained 
non-laminitic or developed laminitis in the following 1, 2 or 3 years. Data were analysed using multivariate logistic regression and significance accepted at 
p<0.05 
Variable All ponies 
n=446 
Laminitic 
after 1 year 
n = 18 
Non 
laminitic 
after 1 year 
n = 428 
P value Laminitic 
after 2 years 
n=30 
Non 
laminitic 
after 2 years 
n=416 
P value Laminitic 
after 3 years 
n=44 
Non laminitic 
after 3 years 
n=402 
P 
value 
Crest height (cm) 5.1  
(3.9, 6.2) 
5.1  
(3.9, 6.1) 
4.9  
(3.9, 6.8) 
0.38 5.1  
(3.9, 6.1) 
5.2  
(4.0, 7.6) 
0.49 5.1  
(3.9, 6.1) 
4.9  
(4.0, 6.9) 
0.72 
Crest thickness (cm) 4.6 + 1.1 4.9 + 0.8 4.6 + 1.1 0.36 5.0 + 1.4 4.6 + 1.1 0.54 4.9 + 1.3 4.6 + 1.1 0.58 
Body condition score 8 (6, 8) 8 (6, 8.25) 8 (6, 8) 0.74 8 (6, 8) 8 (6, 8) 0.73 7.5 (6, 8) 8 (6, 8) 0.38 
Adiponectin (g/ml) 3.72  
(2.55, 5.06) 
1.78  
(1.39, 3.0) 
3.77  
(2.62, 5.06) 
0.04 1.59  
(1.29, 2.49) 
3.87  
(2.71, 5.07) 
0.004 2.15  
(1.42, 4.53) 
3.86  
(2.71, 5.06) 
0.035 
Leptin (ng/ml HE) 3.39  
(1.98, 6.01) 
2.80  
(1.78, 7.90) 
3.41 
(1.98, 5.82) 
0.32 3.93  
(1.98, 6.34) 
3.43  
(1.98, 5.82) 
0.51 3.60 
 (1.98, 4.86) 
3.39  
(1.98, 6.06) 
0.74 
Triglyceride (mmol/l) 0.28  
(0.19, 0.44) 
0.52  
(0.33, 0.63) 
0.27 
(0.19, 0.43) 
0.35 0.48  
(0.21, 0.56) 
0.27  
(0.19, 0.43) 
0.49 0.40  
(0.21, 0.52) 
0.28  
(0.19, 0.43) 
0.98 
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Basal insulin 
(μIU/ml) 
11.9  
(6.6, 30.6) 
68.4  
(20.2, 246.0)  
11.6  
(6.6, 29.77) 
<0.001 68.4  
(21.9, 127.2) 
11.0  
(6.6, 27.9) 
<0.001 42.8  
(21.2, 96.2) 
10.8  
(6.6, 24.6) 
<0.001 
Insulin post 
dexamethasone 
(μIU/ml) 
46.9  
(20.6, 146.6) 
194.0  
(39.6, 418.5) 
46.4  
(20.6, 142.1) 
0.02 269.9  
(60.3, 390.1) 
43.9 
(19.8, 124.5) 
0.002 192.2  
(55.3, 390.1) 
42.5  
(18.4, 121.2) 
<0.001 
CRP (μg/ml) 10.66 
(0.41, 25.97) 
6.16  
(2.85, 15.21) 
10.82  
(0.23, 26.26) 
0.22 6.16  
(1.70, 20.57) 
10.89  
(0.23, 26.26) 
0.10 8.78  
(1.69, 34.13) 
10.80  
(0.23, 25.28) 
0.41 
IGF-1 (ng/ml) 225.8 + 68.9 207.5 + 71.7 226.6 + 68.7 0.25 202.3 + 72.9 227.5 + 68.4 0.033 230.0 + 74.9 225.4 + 68.3 0.67 
IGFBP-1 (ng/ml) 9.70  
(4.18, 25.23) 
10.42  
(4.08, 23.03) 
9.59  
(4.29, 25.41)  
0.33 10.42 
(3.95, 35.84) 
9.59 
(4.29, 25.14) 
0.48 10.27 
(3.44, 35.89) 
9.59 
(4.29, 24.88) 
0.27 
IGFBP-3 (ng/ml) 25.48 
(10.91, 
95.37) 
43.62 
(13.14, 
53.80) 
25.26 
(10.80, 
95.57) 
0.30 29.80  
(9.69, 58.16) 
25.42 
(11.04, 
95.52) 
0.44 25.16 
(10.64, 
53.80) 
25.99 
(10.91, 
98.35) 
0.12 
sE selectin (ng/ml) 3.34 
(1.23, 7.83) 
3.85 
(1.83, 9.82) 
3.21 
(1.23, 7.75) 
0.70 4.76 
(1.15, 10.59) 
3.08 
(1.24, 7.55) 
0.28 3.59 
(1.31, 9.80) 
3.21 
(1.23, 7.44) 
0.60 
P selectin (ng/ml) 3.0 
(1.12, 10.4) 
2.62 
(1.88, 4.41) 
3.04 
(1.11, 11.17) 
0.11 3.22 
(1.82, 11.42) 
3.0 
(1.11, 10.37) 
0.62 2.92 
(1.48, 7.59) 
3.0 
(1.10, 10.59) 
0.68 
vWF Ag (% of 
normal) 
85.0  
(55.0, 117.0) 
63.0  
(44.5, 131.8) 
85.0  
(55.0, 116.0) 
0.54 84.0  
(56.0, 123.0) 
85.0  
(55.0, 116.3) 
0.54 79.5  
(55.0, 116.0) 
85.0  
(55.0, 117.5) 
0.92 
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Table 2 
Analysis of continuous variables put forward into the multivariable model for the future development of laminitis in 446 ponies in 1, 2 and 3 years. 
 Odds Ratio 95% Confidence interval P value 
 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 
Basal insulin 1.50 1.50 1.50 1.48 – 1.55 1.47-1.55 1.48-1.54 <0.001 <0.001 <0.001 
Insulin post 
dexamethasone 
1.22 1.21 1.21 1.10-1.31 1.10-1.32 1.11-1.31 0.001 <0.001 <0.001 
Adiponectin 0.57 0.52 0.64 0.39-0.72 0.38-0.71 0.60-0.81 0.02 <0.001 0.005 
IGF-1  - 0.90 - - 0.84-0.93 - - 0.04 - 
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Table 3 
ROC curve analysis for all of the variables that remained within the multivariable logistic regression models. Cut off values were determined from the co-
ordinates of the ROC curves which maximised the sensitivity and specificity for the ability of the test to divide animals that will and will not develop 
laminitis in the following 1, 2 and 3 years. The corresponding positive (PPV) and negative predictive values (NPV) using these cut-off values were calculated. 
 After 1 year After 2 years After 3 years 
 Adiponectin Basal 
insulin 
Insulin post 
dexamethasone 
Adiponectin Basal 
insulin 
Insulin post 
dexamethasone 
Adiponectin Basal 
insulin 
Insulin post 
dexamethasone 
Area under 
ROC curve 
0.74 0.80 0.67 0.77 0.74 0.69 0.66 0.73 0.69 
95% CI 0.6, 0.88 0.70, 0.90 0.52, 0.83 0.65, 0.88 0.64, 0.85 0.57, 0.81 0.55, 0.77 0.65, 0.81 0.60, 0.78  
Significance <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Cut off 
value 
2.50ng/ml 21.8iu/ml 105.6iu/ml 2.50ng/ml 21.8iu/ml 59.4iu/ml 2.89ng/ml 21.2iu/ml 54.7iu/ml 
Sensitivity 78% 78% 69% 80% 73% 70% 64% 73% 71% 
Specificity 79% 67% 68% 80% 73% 58% 73% 73% 58% 
PPV 13.2% 9.3% 8.3% 22.6% 15.3% 11.3% 20.6% 21.5% 15.8% 
NPV 98.8% 98.6% 98.0% 98.2% 97.3% 96.8% 94.8% 95.9% 95.0% 
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